McKesson (MCK) Stock

Lately, users of Zacks.com have been focusing on McKesson (MCK). Therefore, it's important to take a look at what the stock might offer.

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.

MCK is still growing due to strong performance in different areas and an improved forecast for the fiscal year 2025.

McKesson's cell and gene therapies business is set to provide patients with better treatment choices for sickle cell disease (SCD) thanks to the availability of the FDA-approved drug. This development is anticipated to enhance the care options for those affected by the condition.

McKesson (MCK) has received an upgrade to a Zacks Rank #2 (Buy), indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.

McKesson (MCK) has strong growth characteristics that may enable it to perform better than the market.

No matter if you focus on value, growth, or momentum investing, discovering solid stocks is simpler with the Zacks Style Scores, which is a key part of the Zacks Premium research service.

I maintain a 'Strong Buy' recommendation for McKesson, supported by the growth of GLP-1 drugs and a strong oncology network, with a target price of $696 per share. The company's purchase of a 70% stake in Florida Cancer Specialists strengthens its oncology network, now reaching 3,300 providers in 31 states. Additionally, McKesson reported impressive Q2 results, showing a 21% increase in revenue and raising its EPS forecast to between $32.40 and $33.00, thanks to specialty distribution and retail national account clients.

McKesson's results for the second quarter of fiscal 2025 show an increase in the U.S. Pharmaceutical division. On the other hand, the Medical Surgical Solutions segment is facing challenges because of reduced sales related to COVID.